Antagonism of xylazine induced sedation by idazoxan in calves.
Idazoxan was studied at three dose rates to assess its potential as an antagonist to xylazine. Calves in the study group were initially given xylazine at a dose rate of 0.2 mg/kg intravenously followed 12 minutes later by idazoxan at a dose rate of either 0.05, 0.075 or 0.10 mg/kg intravenously. A control group received a saline injection instead of idazoxan. All three dose levels of idazoxan successfully reversed the xylazine induced central nervous depression and all animals stood within two minutes of injection. No residual signs of sedation were noticed and relapse did not occur. In addition idazoxan was successful in reversing respiratory and cardiovascular depression produced by xylazine. The results indicated that idazoxan may be used for rapid reversal of xylazine induced sedation in calves.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D001784:Blood Gas Analysis / Q000662:veterinary; D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D002417:Cattle / Q000502:physiology*; D004146:Dioxanes / Q000494:pharmacology*; D004147:Dioxins / Q000494:pharmacology*; D006339:Heart Rate / Q000187:drug effects; D006863:Hydrogen-Ion Concentration; D019329:Idazoxan; D008297:Male; D010100:Oxygen / Q000097:blood; D012119:Respiration / Q000187:drug effects; D013843:Thiazines / Q000037:antagonists & inhibitors*; D014991:Xylazine / Q000037:antagonists & inhibitors*
D000317:Adrenergic alpha-Antagonists; D004146:Dioxanes; D004147:Dioxins; D013843:Thiazines; D002245:Carbon Dioxide; D014991:Xylazine; D010100:Oxygen; D019329:Idazoxan